Forbius has dosed the first patient in a Phase IIa triple negative breast cancer (TNBC) clinical trial to evaluate the safety and efficacy of AVID100.

AVID100 is a novel, tumour-selective anti-epidermal growth factor receptor (EGFR) antibody-drug conjugate (ADC).

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

For the multi-centre, dose-expansion Phase IIa trial (AVID100-01; NCT03094169), the efficacy, safety, and tolerability of AVID100 will be assessed in patients with advanced, EGFR-overexpressing TNBC (IHC 2+/3+).

Forbius noted that this is the third cohort that has been launched. It follows earlier cohorts evaluating AVID100 to treat patients with advanced squamous non-small cell lung cancer (sqNSCLC) and squamous cell carcinoma of the head and neck (SCCHN).

“A total of about 100 patients will be evaluated across sqNSCLC, SCCHN, and TNBC, as part of the trial.”

A total of about 100 patients will be evaluated across sqNSCLC, SCCHN, and TNBC, the three EGFR-overexpressing tumour types, as part of the trial.

The highly potent EGFR-targeting ADC, AVID100, has been engineered to achieve enhanced anti-tumour efficacy without a corresponding increase in toxicity in skin or other EGFR-expressing normal tissues.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

A recommended Phase II dose (RP2D) of 220mg/m2 (~6mg/kg) was established for AVID100 in a Phase I study that was completed.

The RP2D is expected to be in the therapeutically active range based on preclinical efficacy studies.

It was found that the majority of treatment-related adverse events in the Phase I trial at the RP2D were well-tolerated.

AVID100-01 is an open-label, multi-centre, dose-expansion study to evaluate the efficacy, safety, and tolerability of AVID100 in patients with confirmed EGFR-overexpressing sqNSCLC (IHC 3+), SCCHN (IHC 3+), and TNBC (IHC 2+/3+).

About 20% of TNBC patients have tumours that highly overexpress EGFR.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact